Our Pipeline


OBE022—Preterm Labor

To date, preterm labor is a condition for which only treatments with limited efficacy or restrictive safety issues are available. This includes the off-label use of tocolytics, which have a limited efficacy in suppressing uterine contractions and delaying birth.

OBE022 is a potential first-in-class, oral and selective prostaglandin F2 alpha receptor antagonist designed to control preterm labor by reducing inflammation, decreasing uterine contractions and preventing cervical changes and membrane ruptures. ObsEva believes this is an innovative approach to controlling preterm labor and delaying birth and OBE022 is being developed as an oral treatment for patients between 24 to 34 weeks of gestation.

ObsEva presented during the second quarter of 2017 key clinical data for the Phase 1 drug-drug interaction study of OBE022 with standard of care treatments for pre-term labor. These data completed the Phase 1 program for OBE022. PROLONG, a phase 2a clinical trial for OBE022 in pre-term labor is expected to commence in the fourth quarter of 2017.

View OBE022 publications here